Trevi Therapeutics, Inc. TRVI

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
39/100
Developing

Ranked against 712 peers in Biotechnology

About Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine … Full TRVI analysis →

Key strengths

  • Strong Liquidity Buffer Liquidity position is strong (score 0.94), providing operational cushion.

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.03), raising refinancing risk.
  • Weak or Negative Cash Flow Cash generation is weak (score 0.00), limiting financial flexibility.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Insufficient Data
—
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where TRVI ranks in Biotechnology

Trevi Therapeutics, Inc. ranks #379 of 713 scored companies in Biotechnology by moat score — the top 53%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
375 Traws Pharma, Inc. TRAW 40/100 Developing
376 Pharvaris N.V. PHVS 39/100 Developing
377 Galecto, Inc. GLTO 39/100 Developing
378 Prothena Corporation plc PRTA 39/100 Developing
379 Trevi Therapeutics, Inc. TRVI 39/100 Developing
380 Lyra Therapeutics, Inc. LYRA 39/100 Developing
381 Veru Inc. VERU 39/100 Developing
382 NRX Pharmaceuticals, Inc. NRXP 39/100 Developing
383 NRx Pharmaceuticals, Inc. NRXPW 39/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How TRVI scores on the Corporate Default defenses

Pricing Power

Not measurable · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Not measurable · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Not measurable · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 40 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 37 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Not measurable · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding TRVI's moat

What is Trevi Therapeutics, Inc.'s moat score?

Trevi Therapeutics, Inc. (TRVI) scores 39 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #379 of 713 scored companies in Biotechnology, the top 53%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Capital Efficiency (40/100) and its weakest is Resilience (37/100).

How does Trevi Therapeutics, Inc. compare with other Biotechnology companies?

Trevi Therapeutics, Inc. ranks #379 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Prothena Corporation plc (PRTA) at 39 just above it and Lyra Therapeutics, Inc. (LYRA) at 39 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Trevi Therapeutics, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Trevi Therapeutics, Inc.?

The Corporate Default template measures 6 defenses, and TRVI scores: Pricing Power (not measurable), Cost Advantage (not measurable), Customer Stickiness (not measurable), Capital Efficiency (40), Resilience (37), Scale & Market Position (not measurable). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000